STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2674 by analyst upside · 2026-06-27
BBNX
Beta Bionics, Inc.
Healthcare · Market Cap $750M · P/E 0x
ANALYST PRICE TARGET
+14.0%
implied upside to consensus target
Current Price $16.82
Consensus Target $19.18
Bull Target $32.0
Bear Target $13.0
Analysts Covering 11
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
7
Hold
3
Sell
0
52-Week Low $8.8
52-Week High $32.71
YTD Return -42.5%
FUNDAMENTALS
Market Cap $750M
P/E Ratio (TTM) N/A
Forward P/E -7.0x
EPS (TTM) $-1.45
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $110M
Profit Margin -60.3%
52-WEEK RANGE
52-Week Low $8.8
52-Week High $32.71
Current Price $16.82
Bear Target $13.0
Bull Target $32.0
● Now $16.82 ● Target $19.18
TRADING DATA
Avg Volume 999K
YTD Return -42.5%
Analyst Count 11
Consensus Buy
Upside to Target +14.0%
Last Updated 2026-06-27

ANALYST SUMMARY

Beta Bionics, Inc. (BBNX) is currently trading at $16.82 with a Wall Street consensus price target of $19.18, implying potential upside of 14.0% over the next 12 months. 11 analysts currently cover BBNX, with a consensus rating of Buy - 73% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $32.0, while the most cautious has a target of $13.0.

BBNX operates in the Healthcare sector with a market capitalisation of $750M. The stock is down 42.5% year-to-date and is currently trading near the lower end of its 52-week range of $8.8 – $32.71.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for BBNX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Goldman Sachs — Reiterated
Buy → Buy 2026-05-27 Building track record
B of A Securities — Reiterated
Neutral → Neutral 2026-05-18 Building track record
Leerink Partners — Reiterated
Outperform → Outperform 2026-04-22 29% win rate (7 calls)
Stifel — Reiterated
Buy → Buy 2026-04-22 Building track record
Truist Securities — Reiterated
Buy → Buy 2026-04-15 Building track record
Goldman Sachs — Reiterated
Buy → Buy 2026-04-09 Building track record
Stifel — Reiterated
Buy → Buy 2026-02-18 Building track record
Baird — Reiterated
Neutral → Neutral 2026-02-18 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
40
out of 100
Coverage depth
19/30
Consensus clarity
7/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →